Subjects are fully eligible for and have completed the AMYPRED-US (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.
(See https://clinicaltrials.gov/ct2/show/NCT04928976)
Subject has access to audio or written recordings created by them that are available for collection.
Subject consents to take part in PAST extension study.
You may not be if
Subject hasn't completed the full visit day in the AMYPRED-US study.
Clareo Health | Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
